University of Rochester
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).
University of Rochester: 636 sponsored US clinical trials, 94 recruiting.
University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.
Top-decile sponsor footprint
University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
636 total, page 5 of 13
Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients
NCT04374760
Effects of a Plant-Based Diet on Insulin Requirements and Obesity Markers in Obese Adults With T2DM
NCT04048642
The Effect of a Mediterranean Diet Intervention on Cancer-related Fatigue and Mitochondrial Function During Chemotherapy
NCT04534738
Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD
NCT06343129
Effects of Home-based Exercise Rehabilitation on Healthcare Utilization in HeartMate 3 Patients
NCT04942353
Baby Formula and Health
NCT04559490
Silverlon to Reduce Radiation Dermatitis
NCT04238728
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
NCT04201834
Engage Psychotherapy to Promote Connectedness in Caregivers
NCT04176601
COVID-19 and Lactating Mothers
NCT04558320
Time-restricted Eating in Cancer Survivorship: A Single-arm Feasibility Pilot Study
NCT04243512
A Pilot Study to Assess the Preliminary Efficacy of EDTA Eye Drops on Band Keratopathy
NCT03985371
Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
NCT04190186
Memory and Attention Adaptation Training-Geriatrics (MAAT-G)
NCT04230941
Hearing Study: Sensitivity to Features of Speech Sounds
NCT03666676
Evaluating the Combined Intervention of Nutritional Supplementation (Remune) and Exercise in Patients With Cancer Cachexia
NCT04131426
Sexual & Gender Minority Competency in Oncology
NCT04198090
Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring
NCT04606134
OptiVol for Precision Medical Management of Heart Failure
NCT04206501
A Mobile Health Exercise Intervention for Older Patients With Myeloid Neoplasms
NCT04035499
Trial of the Families Moving Forward (FMF) Connect Mobile Health Intervention
NCT04194489
Rochester Forensic Assertive Community Treatment Model in Minnesota
NCT07592884
Study of Short Course Radiation Therapy for Elderly Patients With Rectal Cancer
NCT04139967
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
NCT04093531
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
NCT06424795
An Online Cognitive Assessment in Cancer Patients
NCT04667689
Near InfraRed Fluorescence Using Indocyanine Green and Magnetic Resonance Lymphography of Lymphatic Transport
NCT04046146
CogT BEEM Study (a tDCS Study)
NCT04099524
Effects of Whole Food, Plant-Based Nutrition on Chronic Kidney Disease With Proteinuria
NCT04171778
Effects of High Caffeine Content Coffee on Blood Pressure in Young Adults
NCT04060225
Effect of High-Dose Guarana And Cancer-Related Fatigue
NCT03897556
Preventing Premature Death in Patients With Serious Opioid-related Infection
NCT03999450
Mercury Metabolism by Bacteria in Humans
NCT04060212
Translating the ABCS Into HIV Care
NCT03902431
Comparative Effectiveness of EIBI and Adaptive ABA for Children With Autism
NCT04078061
Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma
NCT03229083
Pilot Randomized Trial With Flecainide in ARVC Patients
NCT03685149
Increasing Influenza and Tdap Vaccination of Pregnant Women
NCT04444518
Safety and Efficacy of Chlorthalidone in Type 1 Diabetes
NCT03325114
Stress and Breast Milk Study In the Neonatal Intensive Care Unit
NCT03617549
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
NCT05240339
Wearable Assessments in the Clinic and Home in PD
NCT03681015
Denosumab for Smoldering Multiple Myeloma
NCT03839459
Exercise and Nutrition Interventions During Chemotherapy K07
NCT03858153
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
NCT03788291
Sound Processing Changes in Babies With Opioid Exposure
NCT03567603
Residential Cleaning of Indoor Air to Protect COPD Patients
NCT03750292
Patient Satisfaction Survey of Non-surgical Urinary Incontinence Treatment
NCT04064970
Talk Therapy by Phone to Promote Treatment for Alcohol Problems
NCT03758274
Promotion of Successful Parenting
NCT03808987
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 66 |
| Phase 2 | 81 |
| Phase 3 | 20 |
| Phase 4 | 34 |
Therapeutic Areas
What is open in the University of Rochester pipeline
94 recruiting of 636 indexed (15% open); 448 completed (70%).
Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).
Top condition: Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Rochester: open-pipeline peers nationwide
Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 636 trials (± recruiting share)
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Southern California · 617 trials · 16% recruiting
- Baylor College of Medicine · 616 trials · 15% recruiting
- University of California, Davis · 657 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Loma Linda University · 15% recruiting · 237 trials
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Brown University · 15% recruiting · 231 trials
Related
What to do with this University of Rochester page
636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.
- 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Rochester pipeline card: 636 registered trials from official public datasets.Report a data error.